Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma

被引：420

作者：

Keating, Gillian M. ^{[1
,2
]}

Santoro, Armando ^{[3
]}

机构：

[1] Wolters Kluwer Hlth Adis, Auckland, New Zealand

[2] Wolters Kluwer Hlth, Conshohocken, PA USA

[3] Ist Clin Humanitas, Dept Med Oncol & Hematol, Milan, Italy

来源：

DRUGS | 2009年 / 69卷 / 02期

关键词：

PHASE-I; RAF/MEK/ERK PATHWAY; BAY-43-9006; COMBINATION; THERAPY; CANCER; MODEL; RISK;

D O I：

10.2165/00003495-200969020-00006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sorafenib (Nexavar (R)) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization. Sorafenib is generally well tolerated in patients with advanced hepatocellular carcinoma. Thus, sorafenib represents an important advance in the treatment of advanced hepatocellular carcinoma and is the new standard of care for this condition.

引用

页码：223 / 240

页数：18

共 51 条

[21]

GRETEN T, 2008, 2008 GASTR CANC S JA

[22]

Guan Z, 2008, ANN ONCOL, V19, P168

[23]

*HEINR HEIN U, TACE SOR ADV HEP CAR

[24]

*IT TRIAL MED ONC, PHAS 2 STUD SOR INF

[25] Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics [J].

Lathia, C ;

Lettieri, J ;

Cihon, F ;

Gallentine, M ;

Radtke, M ;

Sundaresan, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) :685-692

[26] Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J].

Liu, Li ;

Cao, Yichen ;

Chen, Charles ;

Zhang, Xiaomei ;

McNabola, Angela ;

Wilkie, Dean ;

Wilhelm, Scott ;

Lynch, Mark ;

Carter, Christopher .

CANCER RESEARCH, 2006, 66 (24) :11851-11858

[27]

Llovet J, 2008, HEPATOLOGY, V48, p372A

[28] Molecular targeted therapies in hepatocellular carcinoma [J].

Llovet, Josep M. ;

Bruix, Jordi .

HEPATOLOGY, 2008, 48 (04) :1312-1327

[29] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

[30] Design and endpoints of clinical trials in hepatocellular carcinoma [J].

Llovet, Josep M. ;

Di Bisceglie, Adrian M. ;

Bruix, Jordi ;

Kramer, Barnett S. ;

Lencioni, Riccardo ;

Zhu, Andrew X. ;

Sherman, Morris ;

Schwartz, Myron ;

Lotze, Michael ;

Talwalkar, Jayant ;

Gores, Gregory J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10) :698-711

← 1 2 3 4 5 6 →